Surveillance of antimicrobial resistance in Neisseria meningitidis strains isolated from invasive cases in Brazil from 2009 to 2016

Gorla, Maria Cecília Outeiro; Pinhata, Juliana Maira Watanabe; Dias, Ueslei José; Moraes, Camile de; Lemos, Ana Paula Silva de

doi:10.1099/jmm.0.000743

Cited by 20 publications

(15 citation statements)

References 38 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…in Argentina, the percentage of MDSP represents 35.4 % [35], 45 % in Italy [36], 57 % in Brazil [37], 67 % in Spain [38] and 21.7 % in Ontario, Canada [39].…”

Section: Discussionmentioning

confidence: 99%

“…In England and Wales, the prevalence of isolates with decreased susceptibility to penicillin was higher in serogroup B isolates [ 34 ]. However in Argentina, the percentage of MDSP represents 35.4 % [ 35 ], 45 % in Italy [ 36 ], 57 % in Brazil [ 37 ], 67 % in Spain [ 38 ] and 21.7 % in Ontario, Canada [ 39 ].…”

Section: Discussionmentioning

confidence: 99%

“…Similar results were found between 1992 and 2000 in Casablanca [ 16 ]. In France, 2 % of the strains isolated between 2012 and 2015 have a decreased susceptibility to C3G, whereas all the strains were sensitive before this date [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Epidemiological profile of Neisseria meningitidis in Casablanca, Morocco: 2010–2019

Mouss

Razki

Hong

et al. 2020

Access Microbiology

View full text Add to dashboard Cite

Surveillance of invasive meningococcal diseases (IMD) must be carried out regularly and continuously in order to detect the emergence of strains of reduced susceptibility to antibiotics for therapeutic and prophylactic use and the appearance of new invasive clones. Molecular-typing approaches allow reliable traceability and powerful epidemiological analysis. This is an epidemiological study of Neisseria meningitidis causing meningitis in Casablanca, Morocco. The grouping was confirmed by PCR mainly on the isolates from cerebrospinal fluid (CSF). A total of 245 confirmed isolates of N .meningitidis were obtained between 2010 and 2019 of which 93 % are of group B. Overall, 24 % of all the isolates have a reduced susceptibility to penicillin G, but no resistance to penicillin G has been reported. All the isolated strains are susceptible to third-generation cephalosporins (3GCs). Genotyping by multilocus sequence typing (MLST) of a selection of 18 strains showed that the majority of isolates belong to the invasive clonal complex CC 32(9/18) followed by the CC 41/44(3/18).

show abstract

“…in Argentina, the percentage of MDSP represents 35.4 % [35], 45 % in Italy [36], 57 % in Brazil [37], 67 % in Spain [38] and 21.7 % in Ontario, Canada [39].…”

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Epidemiological profile of Neisseria meningitidis in Casablanca, Morocco: 2010–2019

Mouss

Razki

Hong

et al. 2020

Access Microbiology

View full text Add to dashboard Cite

show abstract

“…As antimicrobials are used to treat and prevent disease, bacteria can develop resistance ( 112 ). The prevalence of AMR related to IMD serogroups appears limited ( 113 ) (and we are not aware of any evidence specific to serogroup B AMR), but the development of antibiotic resistance in Neisseria meningitidis has been reported in certain settings ( 114 ). Even if meningococcus does not develop resistance, exposure to antibiotics also risks the development of AMR in non-target pathogens 6 .…”

Section: A Taxonomy Of the Full Benefits Of Menb Vaccinationmentioning

confidence: 99%

Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits

Stawasz

Huang

Kirby

et al. 2020

Front. Public Health

View full text Add to dashboard Cite

The high price of new generations of vaccines relative to their predecessors has become an important consideration in debates over whether the benefits of the new vaccines justify their costs. An increasingly central line of inquiry in the literature on valuing vaccination surrounds accounting for the full social and economic benefits of vaccination. This paper applies this emerging perspective to the particular case of vaccination against serogroup B meningococcal disease (MenB). We explore key issues involved in health technology assessments of MenB vaccination, which have led to pronounced heterogeneity in evaluation methods and recommendation outcomes across countries such as France, Germany, the US, and the UK. Accounting for typically neglected sources of socioeconomic benefit could potentially impact recommendation and reimbursement decisions. We propose a taxonomy of such benefits built around four dimensions: (i) internalized health benefits, (ii) internalized non-health benefits, (iii) externalized health benefits, and (iv) externalized non-health benefits. This approach offers a systematic, comprehensive evaluation framework that can be used in future assessment of MenB vaccines as well as other health technologies.

show abstract

“…Although not commonly done, should the microorganism be found to be sensitive to penicillin, therapy of IMD with high-dose penicillin may be considered. Concerningly, isolates of meningococci with decreased susceptibility to penicillin, as well as emerging resistance to other antibiotics, have been recognised in Spain, Europe, South Africa, the US, Canada and Brazil [123–131], with the latter study also reporting resistance of the meningococcus to ciprofloxacin. Alternative drug choices include meropenem (unavailability of a third generation cephalosporin), chloramphenicol (for severe beta-lactam allergy), aztreonam (if chloramphenicol is unavailable in the case of severe beta-lactam allergy), or a fluoroquinolone, such as moxifloxacin (currently restricted in the US, due to consideration of meningococcal fluoroquinolone resistance and lack of controlled trials in IMD) [7].…”

Section: Introductionmentioning

confidence: 99%

Meningococcal pneumonia: a review

Feldman

Anderson

2019

Pneumonia

View full text Add to dashboard Cite

Background Although Neisseria meningitidis is one of the major causes of meningitis, meningococcal pneumonia is the most common non-neurological organ disease caused by this pathogen. Methods We conducted a review of the literature to describe the risk factors, pathogenesis, clinical features, diagnosis, treatment and prevention of meningococcal pneumonia. Results Meningococcal pneumonia was first described in 1907 and during the 1918–1919 influenza pandemic large numbers of cases of meningococcal pneumonia occurred in patients following the initial viral infection. A number of publications, mainly case series or case reports, has subsequently appeared in the literature. Meningococcal pneumonia occurs mainly with serogroups Y, W-135 and B. Risk factors for meningococcal pneumonia have not been well characterised, but appear to include older age, smoking, people living in close contact (e.g. military recruits and students at university), preceding viral and bacterial infections, haematological malignancies, chronic respiratory conditions and various other non-communicable and primary and secondary immunodeficiency diseases. Primary meningococcal pneumonia occurs in 5–10% of patients with meningococcal infection and is indistinguishable clinically from pneumonia caused by other common pathogens. Fever, chills and pleuritic chest pain are the most common symptoms, occurring in > 50% of cases. Productive sputum and dyspnoea are less common. Diagnosis of meningococcal pneumonia may be made by the isolation of the organism in sputum, blood, or normally sterile site cultures, but is likely to underestimate the frequency of meningococcal pneumonia. If validated, PCR-based techniques may be of value for diagnosis in the future. While penicillin was the treatment of choice for meningococcal infection, including pneumonia, prior to 1991, a third generation cephalosporin has been more commonly used thereafter, because of concerns of penicillin resistance. Chemoprophylaxis, using one of a number of antibiotics, has been recommended for close contacts of patients with meningococcal meningitis, and similar benefits may be seen in contacts of patients with meningococcal pneumonia. Effective vaccines are available for the prevention of infection with certain meningococcal serogroups, but this field is still evolving. Conclusion Meningococcal pneumonia occurs fairly frequently and should be considered as a possible cause of pneumonia, particularly in patients with specific risk factors.

show abstract

Surveillance of antimicrobial resistance in Neisseria meningitidis strains isolated from invasive cases in Brazil from 2009 to 2016

Cited by 20 publications

References 38 publications

Epidemiological profile of Neisseria meningitidis in Casablanca, Morocco: 2010–2019

Epidemiological profile of Neisseria meningitidis in Casablanca, Morocco: 2010–2019

Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits

Meningococcal pneumonia: a review

Contact Info

Product

Resources

About